George MD, et al. - Using national US Veteran's Affairs databases 2005–2016, investigators analyzed the predictors of higher use of biologic therapies and also to identify the factors correlated with persistent glucocorticoid use. They observed a substantial lower use of biologic in older candidates [for cases ≥ 80 vs < 50] and subjects with more comorbidities [Charlson score ≥ 3 vs < 3]. Biologic were less likely to be used in individuals with heart failure, cancer, and among nonwhite candidates. They also noted the frequent use of glucocorticoid in subjects with comorbidities, with implications for patient outcomes. They found comparable glucocorticoid use irrespective of age among individuals who were avoiding biologics because of safety concerns.